Ramantamig

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A T-cell engager and trispecific antibody targeting the two tumor-associated antigens (TAAs) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and human G-protein coupled receptor family C group 5 member D (GPRC5D), and the T-cell surface antigen CD3, with potential immunomodulating and antineoplastic activities. Upon administration, ramantamig simultaneously targets and binds to BCMA and GPRC5D expressed on tumor cells, and CD3 expressed on T-cells. The resulting cross-linkage activates and redirects CTLs to GPRC5D- and BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival. GPRC5D is overexpressed on certain tumors, including multiple myeloma, while minimally expressed on normal, healthy cells, and plays a key role in tumor cell proliferation.

**Synonyms:** - Anti-BCMA/Anti-GPRC5D/Anti-CD3 Trispecific Antibody JNJ-79635322 - Anti-BCMA/GPRC5D/CD3 Trispecific Antibody JNJ-79635322 - BCMA/GPRC5D/CD3 T-cell Engager JNJ-79635322 - BCMA/GPRC5D/CD3 TCE JNJ-79635322 - BCMAxGPRC5DxCD3 Trispecific Antibody JNJ-79635322 - JNJ 79635322 - JNJ-79635322 - JNJ79635322 - RAMANTAMIG